Suppressed miR-128-3p combined with TERT overexpression predicts dismal outcomes for neuroblastoma

Abstract

BACKGROUND:

Molecular and clinical diversity of neuroblastomas is notorious. The activating TERT rearrangements have been associated with dismal prognosis. Suppression of miR-128-3p may complement and enhance the adverse effects of TERT overexpression.

OBJECTIVE:

The study aimed at evaluation of prognostic significance of the miR-128-3p/TERT expression in patients with primary neuroblastoma.

METHODS:

RNA samples isolated from fresh-frozen tumor specimens ( $n=$ 103) were reverse transcribed for evaluation of miR-128-3p and TERT expression by qPCR. The normalized expression levels were tested for correlations with the event-free survival (EFS). ROC-analysis was used to establish threshold expression levels (TLs) for the possible best prediction of the outcomes. The median follow-up was 57 months.

RESULTS:

Both TERT overexpression and miR-128-3p downregulation were independently associated with superior rates of adverse events ( $p=$ 0.027, TL $=-$ 2.32 log ${}_{10}$ and $p=$ 0.080, TL $=-$ 1.33 log ${}_{10}$ , respectively). The MYCN single-copy patients were stratified into groups based on the character of alterations in expression of the studied transcripts. Five-year EFS in the groups of patients with elevated TERT/normal miR-128-3p expression and normal TERT/reduced miR-128-3p expression were 0.74 $\pm$ 0.08 and 0.60 $\pm$ 0.16, respectively. The patients with elevated TERT/reduced miR-128-3p expression had the worst outcomes, with 5-year EFS of 0.40 $\pm$ 0.16 compared with 0.91 $\pm$ 0.06 for the patients with unaltered levels of both transcripts ( $p<$ 0.001). Cumulative incidence of relapse/progression for the groups constituted 0.23 $\pm$ 0.08, 0.40 $\pm$ 0.16, 0.60 $\pm$ 0.16 and 0.09 $\pm$ 0.06, respectively. Moreover, the loss of miR-128-3p was qualified as independent adverse predictor which outperformed the conventional clinical and genetic risk factors in the multivariate Cox regression model of EFS.

CONCLUSIONS:

Combined expression levels of miR-128-3p and TERT represent a novel prognostic biomarker for neuroblastoma.

Keywords

Neuroblastoma miR-128-3p expression prognosis

1. Introduction

Neuroblastoma is the most common extracranial solid malignancy of childhood. Its clinical behavior varies widely from the relatively benign forms prone to spontaneous regression or maturation to the highly aggressive tumors with high relapse rates, treatment resistance and dismal outcomes. Diverse genetic characteristics of neuroblastoma cells determine the clinical heterogeneity and can be utilized as prognostic markers. Common aberrations used for the prognosis and clinical stratification of neuroblastoma include MYCN amplification (MNA) and chromosome 1p and 11q deletions [1, 2]. The list of prognostically significant copy number alterations and gene expression signatures is being constantly updated with the use of high-throughput molecular approaches [3, 4].

Activating rearrangements in TERT promoter have been recently associated with aggressive neuroblastoma [5]. These aberrations cause telomerase overexpression leading to the abnormal telomere maintenance; a similar effect is conferred by MYCN amplification [5]. When coupled with pathogenic mutations in the components of RAS and TP53 pathways, TERT aberrations determine extremely high risks; in the absence of complementing mutations, the abnormal telomere maintenance is still an unfavorable prognostic factor. Strong association of TERT rearrangements with a number of unfavorable genomic and transcriptomic signatures has been demonstrated [6].

The protein-encoding gene expression profiling of neuroblastoma revealed distinct mRNA signatures associated with favorable and adverse courses of the disease [7, 8, 9]. Significance of the matching microRNA expression profiles remains ambiguous. Preclinical findings indicate that microRNAs may promote (miR-332-3p, miR-3934-5p, miR-146b) as well as suppress (miR-15a-5p, miR-15b-5p, miR-16-5p, miR-34a, miR-145, miR-149, miR-429, miR-490-5p) the viability of neuroblastoma cells with corresponding influence on the survival [10, 11, 12, 13, 14, 15, 16, 17, 18].

Small non-coding RNA hsa-miR-128-3p (miR-128-3p, formerly known as hsa-miR-128a) is a candidate tumor suppressor microRNA. In normal conditions its expression is restricted to nervous tissue [19] but miR-128-3p is abundantly expressed in various malignancies including head and neck squamous carcinoma, hepatocellular carcinoma, lung cancer, gastric cancer and glioblastoma [20, 21, 22, 23, 24]. The mature isoform of miR-128-3p specifically targets mRNA molecules of cancer-related genes involved in cell cycle and apoptosis control (E2F3, E2F6, E2F7, BMI1, SPTAN1, BAX, BCL2), JAK-STAT and receptor tyrosine kinase pathways (JAK1, PDGFRA, PDGFRB, NTRK2, NTRK3, RPS6KB2) and angiogenesis (VEGFB, VEGFC) [20, 22, 23, 25, 26, 27].

A number of findings suggest that miR-128-3p may act as a tumor suppressor in neuroblastoma cells. For instance, miR-128-3p inhibits cellular motility and invasiveness and induces proliferation arrest and apoptosis by targeting RELN, DCX and HOXA7 genes [28, 29]. Bao et al. identified SNHG16 (long non-coding RNA associated with neuroblastoma aggressiveness) as a direct inhibitor of miR-128-3p. Expression of miR-128-3p is significantly reduced in neuroblastoma specimens (compared to the normal tissue of adrenal medulla or sympathetic ganglia) while being upregulated during the retinoid acid-induced differentiation of neuroblastoma cells [29]. According to Roy et al., miR-128-3p can block WNT signaling by targeting its key components (including WNT5B, DVL and LEF1) [30].

At the same time, the possible role of miR-128-3p in neuroblastoma progression is ambiguous. Other reported targets of miR-128-3p include the truncated isoform of NTRK3, which participates in membrane remodeling and reorganization of the cytoskeleton but cannot support the transduction of proliferative signals like the full-length isoform [25]. Moreover, overexpression of miR-128-3p in SH-SY5Y neuroblastoma cell cultures leads to upregulation of BCL2, ETS1, ETV4 and CCND2 resulting in the immature phenotype (rounded cell bodies, shorter neurites and smaller cell size) and apoptosis inhibition thus acting as an oncogenic event [25].

Clinical significance of miR-128-3p expression in neuroblastoma was evaluated just once by Evangelisti et al. on the limited cohort of patients. The study revealed the association of high miR-128-3p levels with favorable indicators such as early age at diagnosis, favorable Shimada category, localized and 4S stages and the absence of MYCN amplification [28].

In this study, we evaluate clinical significance of hsa-miR-128-3p expression in primary neuroblastomas with diverse molecular contexts including known prognostic factors, including overexpression of TERT.

Table 1
Nucleotide sequences of primers and probes used for reverse transcription reaction and qPCR

Oligonucleotide name	5’-3’ sequence
miR-128-3p stem-loop RT primer	GTC-GTA-TCC-AGT-GCA-GGG-TCC-GAG-GTA-TTC-GCA-CTG-GAT-ACG-ACA-AAG-AG
miR-128-3p forward primer	ACC-CGT-CAC-AGT-GAA-CCG
miR-128-3p reverse primer	GTG-CAG-GGT-CCG-AGG-T
miR-128-3p probe	FAM-CGC-ACT-GGA-TAC-GAC-AAA-GAG-AAA-GAG-ACC-GGT-BHQ1
TERT forward primer	ACC-GTC-TGC-GTG-AGG-AGA-TC
TERT reverse primer	TTG-CTC-CAG-ACA-CTC-TTC-CG
TERT probe	ROX-TGT-ACG-TCG-TCG-AGC-TGC-TCA-GGT-CTT-T-BHQ2
ACTB forward primer	CTG-GCA-CCA-CAC-CTT-CTA-CA
ACTB reverse primer	TAG-CAA-CGT-ACA-TGG-CTG-GG
ACTB probe	FAM-CAA-GGC-CAA-CCG-CGA-GAA-GAT-GAC-C-BHQ1

2. Materials and methods

2.1 Experimental subjects

The study was approved by the Local Ethics Committee of Regional Children’s Hospital, Yekaterinburg, Russian Federation. The written informed consent was obtained from parents or legal representatives of all patients. Totally, 103 patients admitted to the Pediatric Oncology and Hematology Center during the period 02/2005–04/2014 were enrolled in the study. The inclusion criteria were histopathologically verified neuroblastoma and the availability of fresh-frozen tumor samples. Of the studied cohort, 68 (66%) patients had localized tumors, 26 (25%) patients were diagnosed with stage 4 disease and 9 (9%) had stage 4S disease as defined by INSS criteria. In terms of molecular characterization, 16 (15%) patients harbored MYCN amplification and 22 (21%) had chromosome 1p deletions. Forty-six (45%) patients were under 12 months of age at the time of diagnosis. All patients were managed according to the NB2004 protocol of German Society of Pediatric Oncology and Hematology, (GPOH), with 61 (59%) patients assigned to the observation group, 11 (11%) to the intermediate risk group and 31 (30%) to the high-risk group.

2.2 Molecular genetic techniques

Total RNA and genomic DNA were extracted from fresh-frozen tumor tissues with TRI-reagent (Molecular Research Center, USA) and Wizard Genomic DNA Purification Kit (Promega, USA), respectively. In a pilot series of experiments, the RNA samples were enriched with a pool of short fragments extracted from 10 tissue specimens using mirVana miRNA Isolation Kit (Ambion, USA). As the enrichment showed no significant influence on the miR-128-3p quantification, all subsequent experimental workflow was conducted on the total RNA. The MMLV reverse transcriptase-mediated first strand cDNA synthesis was carried out using 1 $\mu$ g of total RNA, with d(N9) random primer for the detection of TERT and ACTB protein-coding transcripts and stem-loop primer for the detection of mature miR-128-3p. The reverse transcription products were used for ACTB, TERT and miR-128-3p quantification in an Agilent Mx3005P qPCR System (Agilent, USA) using oligonucleotide primers and probes developed by Syntol LLC and listed in the Table 1. The quantification standards were provided by the manufacturer; the expression values were calculated as 10 ${}^{(\text{Cq-Yintersept})/\text{slope}}$ and after normalization represented in log ${}_{10}$ .

To validate the results of miR-128-3p quantification, independent analysis was implemented using molecular “barcodes” (NanoString) technology with nCounter ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ Human v3 miRNA Expression Assay Kit (NanoString Technologies, USA) for a randomly selected subset of 25 cases (Supplementary Table 1). The use of total RNA as a starting material enabled the use of protein-coding reference transcripts for normalization of both TERT and miR-128-3p expression levels as recommended by the manufacturer (NanoString Technologies). The qPCR data were normalized by relating copy numbers of the target (TERT or miR-128-3p) to ACTB (NM_001101.2) copy numbers, which was selected as a reference gene. The same ACTB reference transcript was combined with $B2M$ (NM_004048.2), GAPDH (NM_002046.3), RPL19 (NM_000981.3) and RPLP0 (NM_001002.3) reference transcripts for NanoString data normalization. The analysis was performed in nSolver™Analysis Software (NanoString Technologies).

MNA and 1p36 deletions were assessed by fluorescence in situ hybridization (FISH) with N-MYC, 2p24.3, Red and LAF4, 2q11.2, Green probe combination (Cytocell, UK); and SRD (CHD5), 1p36.31, Red and 1qter, 1q44, Green combination (Cytocell).

2.3 Statistics

Statistical analysis was performed in XLstat software (Addinsoft, USA). The quantitative data distribution fitting was evaluated by Shapiro-Wilk, Anderson-Darling and Lilliefors tests. The measured values of TERT and miR-128-3p expression did not follow a normal distribution (all $p$ values $<$ 0.001). ROC-analysis was applied to determine the thresholds of TERT and miR-128-3p expression for the most informative patient’s stratification. Between-group differences in the expression of the studied markers were evaluated by Mann-Whitney test. Prognostic significance of TERT and miR-128-3p expression levels was determined by calculating 5-year event-free survival (EFS) using Kaplan-Meier method. Significance of the differences in survival probability and cumulative incidence of tumor relapse or progression (CIRP) were determined by log-rank and Gray tests, respectively. For multiple comparisons, Dunn-Šidàk correction was applied to calculate the adjusted $p$ -values. Prognostic correlations of TERT and miR-128-3p expression levels and other known risk factors with unfavorable events (hazard ratios, HR) were studied using Cox proportional-hazards model and Wald test. The median follow-up was 57 months (within the total range of 13–209 months). Bland-Altman test was used to assess the quantitative agreement between the results of miR-128-3p quantification by qPCR and NanoString based on the mean difference and standard deviation.

3. Results

The normalized expression of TERT ranged from $-$ 4.04 log ${}_{10}$ to 0.04 log ${}_{10}$ (median $-$ 2.05 log ${}_{10}$ ). Consistently with previous findings [5, 6], the elevated levels of TERT expression positively correlated with superior rates of tumor progression and recurrence ( $p=$ 0.027). The determined threshold level of $-$ 2.32 log ${}_{10}$ , corresponding to 0.620 area under ROC-curve, enabled stratification with possible best sensitivity and specificity. MYCN amplification, known to be a direct activator of TERT, was associated with higher TERT expression (median $-$ 1.38 log ${}_{10}$ compared to $-$ 2.13 log ${}_{10}$ for the rest of the cohort, $p=$ 0.058).

The normalized expression of miR-128-3p ranged from $-$ 2.90 log ${}_{10}$ to 3.11 log ${}_{10}$ (median $-$ 0.23) and its levels negatively correlated with the rates of tumor-specific adverse events. Patients harboring miR-138-3p expression levels equal or above $-$ 1.33 log ${}_{10}$ , corresponding to 0.615 area under ROC-curve, were at low risks of recurrence or progression of the disease ( $p=$ 0.080). As expected, MNA tumors demonstrated significantly reduced miR-128-3p levels compared to non-MNA (single-copy MYCN) tumors (median $-$ 1.33 log ${}_{10}$ vs. $-$ 0.18 log ${}_{10}$ , respectively; $p=$ 0.019).

As patients with MNA tumors have the worst prognosis, to avoid the bias in subsequent Cox regression analysis, the patients with MNA were sorted out into a separate group ( $n=$ 16). The non-MNA patients were divided into four groups based on the levels of normalized TERT and miR-128-3p expression:

patients with TERT expression below $-$ 2.32 log ${}_{10}$ and miR-128-3p levels above $-$ 1.33 log ${}_{10}$ ( $n=$ 23);

patients with TERT expression above $-$ 2.32 log ${}_{10}$ and miR-128-3p levels above $-$ 1.33 log ${}_{10}$ ( $n=$ 44);

patients with TERT expression below $-$ 2.32 log ${}_{10}$ and miR-128-3p levels below $-$ 1.33 log ${}_{10}$ ( $n=$ 10);

patients with TERT expression above $-$ 2.32 log ${}_{10}$ and miR-128-3p levels below $-$ 1.33 log ${}_{10}$ ( $n=$ 10).

Group 1 consisted predominantly of low-risk patients with localized tumors, whereas groups 2–4 consisted of patients with diverse risk status harboring localized or metastatic tumors. 1p deletion was distributed randomly across the groups showing no association with TERT and miR-128-3p expression levels. In general, expression of the studied markers and the presence of MNA were major determinants of survival rates for the entire cohort (Table 2).

Table 2
Risk indicators (EFS, CIRP) with molecular and clinical characterization of tumors for the cohort stratified by MYCN amplification (MNA) and TERT/miR-128-3p expression in non-MNA cases

Feature	Group 1	Group 2	Group 3	Group 4	MNA
Number of patients	23	44	10	10	16
NB2004 risk-group distribution
Observation group	20	29	7	5	0
Intermediate risk group	3	6	1	1	0
High-risk group	0	9	2	4	16
INSS stage distribution
1	10	20	5	2	2
2	0	4	1	0	1
3	9	6	1	2	5
4	1	11	2	5	7
4S	3	3	1	1	1
1p deletions	2	8	1	1	10
Median of log ${}_{10}$ TERT	$-$ 2.99 ( $-$ 4.04 …	$-$ 1.18 ( $-$ 2.30 …	$-$ 2.66 ( $-$ 3.28 …	$-$ 2.06 ( $-$ 2.32 …	$-$ 1.38 ( $-$ 3.20 …
expression (range)	$-$ 2.36)	0.04)	$-$ 2.36)	$-$ 0.94)	0.02)
Median of log ${}_{10}$ miR-128-3p	$-$ 0.20 ( $-$ 1.33 …	0.44 ( $-$ 1.32 …	$-$ 1.64 ( $-$ 2.80 …	$-$ 2.00 ( $-$ 2.76 …	$-$ 1.33 ( $-$ 2.90 …
expression (range)	0.95)	3.08)	$-$ 1.36)	$-$ 1.42)	3.11)
5-year EFS	0.91 $\pm$ 0.06	0.74 $\pm$ 0.08	0.60 $\pm$ 0.16	0.40 $\pm$ 0.16	0.25 $\pm$ 0.11
CIRP	0.09 $\pm$ 0.06	0.23 $\pm$ 0.08	0.40 $\pm$ 0.16	0.60 $\pm$ 0.16	0.75 $\pm$ 0.11

The patients with unaltered levels of TERT mRNA and miR-128-3p (group 1) had favorable outcomes, with only two patients of this group experiencing disease progression (EFS 0.91 $\pm$ 0.06, CIRP 0.09 $\pm$ 0.06). In contrast, TERT overexpression combined with the loss of miR-128-3p (group 4) was associated with the worst outcomes including three cases of disease progression, three cases with metastatic recurrence and one case of local relapse (EFS 0.40 $\pm$ 0.16, CIRP 0.60 $\pm$ 0.16). The groups of patients with either elevated TERT expression or downregulated miR-128-3p (groups 2 and 3) showed intermediate EFS and CIRP, 0.74 $\pm$ 0.08; 0.60 $\pm$ 0.16 and 0.23 $\pm$ 0.08; 0.40 $\pm$ 0.16, respectively (Tables 2 and 3, Fig. 1). Notably, all adverse events observed in the studied cohort with the exception of one death due to treatment complications in group 2, were disease-related.

Table 3

Comparisons of survival probability between the analyzed groups ( $p$ -values adjusted with the use of Dunn-Šidàk correction)

	Group 2	Group 3	Group 4	MNA
Group 1	0.893	0.313	0.010	$<$ 0.001
Group 2	–	0.920	0.024	$<$ 0.001
Group 3		–	0.992	0.786
Group 4			–	0.994

Figure 1.

Prognostic significance of TERT/miR-128-3p expression levels (groups 1–4, lines 1–4) and MYCN amplification (lines 5) assessed by EFS (A) and CIRP (B).

Table 4

Cox regression analysis of survival probability for the entire cohort

Covariate	Number of patients	Number of events	Hazard ratio	95% CI	$p$	Hazard ratio	95% CI	$p$
			Univariate analysis			Multivariate analysis
Stage
1–3, 4S	77	17	1		$<$ 0.001	1		0.610
4	26	18	4.04	2.07–7.89		1.31	0.46–3.73
Age at the time of diagnosis
$<$ 18 months	54	12	1		0.010	1		0.386
$>$ 18 months	49	23	2.52	1.25–5.08		1.40	0.65–3.00
Risk group
Observation and intermediate-risk groups	72	12	1		$<$ 0.001	1		0.118
High-risk group	31	23	6.59	3.26–13.31		2.96	0.76–11.52
MYCN status
Non-amplified	87	23	1		$<$ 0.001	1		0.236
Amplified	16	12	4.63	2.29–9.39		1.90	0.66–5.46
1p deletion
Absence	81	24	1		0.071	1		0.344
Presence	22	11	1.93	0.95–3.96		0.65	0.26–1.60
Normalized TERT expression
Below threshold	35	6	1		0.028	1		0.273
Above threshold	68	29	2.69	1.11–6.49		1.71	0.66–4.43
Normalized expression of miR-128-3p
Above threshold	75	18	1		$<$ 0.001	1		0.019
Below threshold	28	17	3.29	1.69–6.39		2.35	1.15–4.80

Table 5

Cox regression analysis of survival probability for the non-MNA group (single-copy MYCN patients)

Covariate	Number of patients	Number of events	Hazard ratio	95% CI	$p$	Hazard ratio	95% CI	$p$
			Univariate analysis			Multivariate analysis
Stage
1–3, 4S	68	11	1		$<$ 0.001	1		0.290
4	19	12	4.99	2.19–11.35		3.21	0.37–27.93
Age at the time of diagnosis
$<$ 18 months	50	9	1		0.041	1		0.148
$>$ 18 months	37	14	2.40	1.04–5.56		2.04	0.78–5.36
Risk group
Observation and intermediate-risk groups	72	12	1		$<$ 0.001	1		0.922
High-risk group	15	11	5.67	2.48–12.92		1.12	0.11–11.08
1p deletion
Absence	75	18	1		0.220	1		0.423
Presence	12	5	1.87	0.69–5.05		1.54	0.54–4.44
Normalized TERT expression
Below threshold	33	6	1		0.287	1		0.873
Above threshold	54	17	1.66	0.65–4.24		1.09	0.37–3.23
Normalized expression of miR-128-3p
Above threshold	67	12	1		0.002	1		0.012
Below threshold	20	11	3.74	1.65–8.50		3.16	1.28–7.77

Figure 2.

Bland-Altman plot showing agreement of the miR-128-3p expression obtained by qPCR and NanoString assay. Horizontal axis represents mean of miR-128-3p normalized expression assessed by two techniques, vertical axis shows difference between the methods; line A represents the mean difference ( $-$ 1.17) with 95% CI $-$ 1.64 … $-$ 0.71 (lines B); lines C represent the limits of agreement (mean difference $\pm$ 1.96 $\times$ SD, $-$ 3.37 … 1.02).

The univariate analysis of EFS in the entire cohort confirmed the adverse prognostic significance for a number of risk factors, both clinical (stage 4 of the disease, age at the diagnosis over 18 months and the assignment to high-risk group according to the NB2004 stratification scheme) and molecular (MNA, TERT/miR-128-3p profiles). Noteworthy, the loss of miR-128-3p expression was the only significant risk factor identified by the multivariate analysis, HR 2.35, $p=$ 0.019 (Table 4). It outperformed such strong risk factors as MNA, stage 4 of the disease and the assignment to the NB2004 high-risk group. Finally, the multivariate analysis of EFS in non-MNA patients also pointed to the loss of miR-128-3p expression as the independent adverse predictor HR 3.16, $p=$ 0.012 (Table 5). The implicated high significance of miR-128-3p expression levels required independent reciprocal confirmation by an alternative method. A randomly selected subset of 25 samples representing different groups (TERT/miR-128-3p groups 1-4 and MNA, Supplementary Table 1) were tested for the expression of miR-128-3p by using the molecular “barcodes” (NanoString) technology with raw counts normalized against a set of five reference transcripts. The log ${}_{10}$ of normalized miR-128-3p counts ranged from 0 to 1.94 (median 0.20) while log ${}_{10}$ of the normalized miR-128-3p expression assessed by qPCR ranged from $-$ 2.76 to 1.44 (median $-$ 0.67). Bland-Altman analysis (Fig. 2) showed that the bias (mean difference) was $-$ 1.17, with a standard deviation (SD) of 1.12. For the vast majority of measurements (24 of 25, 96%), the results showed marked pairwise consistency of miR-128-3p expression results obtained with the two platforms, falling within the $\pm$ 1.96 SD limit of agreement ( $-$ 3.37 … 1.02).

4. Discussion

According to the recent mechanistic classification of clinical phenotypes in neuroblastoma introduced by Ackermann et al., abnormal telomere maintenance via TERT activation or alternative pathway is strongly associated with the tumor aggressiveness. When complemented by pathogenic mutations in RAS and/or TP53 pathway components, the abnormal telomere lengthening determines the most adverse clinical course. Moreover, it has been linked to other known risk factors including segmental chromosomal aberrations and unfavorable gene expression signatures [6].

A number of preclinical findings suggest that miR-128-3p acts as a tumor suppressor by switching off the expression of cancer-related genes in various malignancies [20, 21, 22, 23, 24]. In neuroblastoma models, miR-128-3p specifically reduced the expression of oncogenic transcription factors, regulators of cell migration and components of RAS and WNT signaling, thus inhibiting the viability and metastatic potential of tumor cells [28, 29, 30]. However, the opposing line of evidence points to oncogenic effects of miR-128-3p overexpression, for example, the immature phenotypes, increased proliferation rates and apoptosis inhibition in neuroblastoma cell lines [25]. The only reported evaluation of clinical significance of miR-128-3p expression in neuroblastoma supports the association of its high levels with favorable course of the disease [28].

Our data demonstrate synergistic impact of TERT overexpression and miR-128-3p downregulation on the disease-specific survival of patients with neuroblastoma. The patients manifesting both alterations showed low EFS and high disease progression rates resembling the effects of MYCN amplification. By contrast, preserved miR-128-3p expression in the absence of TERT activation was associated with favorable outcomes. Disparate manifestations of either TERT upregulation or the loss of miR-128-3p expression were associated with intermediate EFS and CIRP values. The conventional risk factors showed no extra-significance for survival to the TERT/miR-128-3p expression modes. In the multivariate analysis, these factors were outperformed by the level of miR-128-3p expression as a covariate. The obtained qPCR measurements of miR-128-3p expression showed agreement with the results of NanoString assay, which is an excellent independent tool for the validation of qPCR data due to the absence of reverse transcription, and amplification reactions in the protocol and consequently the lack of bias associated with these steps.

Characteristic gene expression signatures identified by different research groups enable the use of transcriptomic approaches for the prediction of neuroblastoma outcomes. MicroRNAs, a subtype of small non-coding RNA molecules, target a variety of transcripts and work as pivotal negative regulators of gene expression at the post-transcriptional level. Noteworthy, 16 out of 194 transcripts included in the SVM_th10 neuroblastoma classifier developed by Oberthuer at al. [8] are predicted targets of miR-128-3p listed in the miRDB target prediction database [26]. Of those 16 transcripts, PHLDA2, AGRN, DIRAS1, TCEANC2, NCAN, NXT2, KPNB1, RLIM, MED14 and ZBTB20 have been positively associated with adverse phenotypes of neuroblastoma, including drug resistance, whereas high expression levels of BAZ2B, NCOA7, WSB1, RFX3, PGM2L1 and CNR1 correlate with favorable clinical course [31, 32, 33, 34, 35, 36, 37, 38, 39].

Considering that microRNAs naturally inhibit gene expression at the post-transcriptional level, direct binding of the preserved miR-128-3p to TERT mRNA would be a straightforward explanation for the observed inhibition of TERT. However, neither predicted nor de facto targets of miR-128-3p include TERT. At the same time, several positive regulators of telomerase activity are definitely controlled by miR-128-3p. These include BMI1 capable of inducing telomerase activity in different cell types, normal or pathologically altered. For instance, hematopoietic stem cells (HSCs) harbor high expression levels of BMI1, which decline upon HSC differentiation towards partially committed precursors [40]. Furthermore, BMI1 has been shown to promote self-renewal of neural stem cells (and HSCs as well) by tuning the balance between differentiation and the undifferentiated cell growth [41, 42]. Upregulation of TERT by BMI1 has been observed in breast and ovarian cancers [43, 44] and nasopharyngeal carcinoma [45]. Noteworthy, in these cancers, TERT is activated independently of MYC or MYCN transcription factors [46]. The BMI1-dependent activation of TERT is cell type-selective: for instance, overexpression of BMI1 in fibroblasts does not promote excessive telomerase activity and immortalization [47]. Although no immediate effect of BMI1 on TERT has been demonstrated for neuroblastoma cells, BMI1 expression is prerequisite for the malignant transformation of neuroblasts and initiation of neuroblastoma tumorigenesis in immunodeficient mice [48, 49, 50].

Other known miR-128-3p-dependent positive regulators of telomerase activity are RUVBL2, NHP2, and PRKCB [19, 26, 27]. The RUVBL2 ATPase ensures interaction of DKC1/TERC complex with the TERT catalytic subunit, thus enabling the synthesis of telomeric DNA repeats. NHP2 (jointly with DKC1) participates in the H/ACA small nucleolar ribonucleoprotein complex (H/ACA snoRNP) responsible for the assembly of pivotal cellular RNPs; apart from its role in ribosome biosynthesis, the complex is involved in processing of TERC – the RNA component of TERT holoenzyme [51, 52]. The diverse functionalities of PRKCB, Protein Kinase C Beta type, include TERT activation, while its own PRKCB mRNA is targeted by miR-128-3p [19, 26]. Thus, despite the lack of direct destabilizing action of miR-128-3p on TERT mRNA, inhibition of telomerase activity under preserved expression of miR-128-3p can be achieved by inhibitory effects of this microRNA on translation of particular proteins essential for telomerase activity.

5. Conclusions

The study identifies the loss of miR-128-3p expression as a novel, potentially clinically relevant marker of aggressive neuroblastoma. The loss of miR-128-3p expression effectively complements TERT activation which is typical for high-risk tumors. The combination of two markers defines the adverse course of the disease indistinguishable from the effects of MYCN amplification. Downregulation of miR-128-3p with concomitant TERT upregulation is a promising prognostic criterion of adverse neuroblastoma for prospective validation in clinical trials.

Ethical statement

The study was approved by the Local Ethics Committee of Regional Children’s Hospital, Yekaterinburg, Russian Federation.

The study was supported by the Charity foundation Podari.Life.

Author contributions

Conception: Druy A.E., Tsaur G.A.

Interpretation or analysis of data: Druy A.E., Tsaur G.A., Shorikov E.V., Tytgat G.A.M., Fechina L.G.

Preparation of the manuscript: Druy A.E.

Revision for important intellectual content: Druy A.E., Tsaur G.A., Shorikov E.V., Tytgat G.A.M., Fechina L.G.

Supervision: Fechina L.G.

Footnotes

Acknowledgments

The authors thank Alena Alekseeva (BioVitrum LLC) for providing nCounter ${}^{\@setsize{\scriptsize}{8pt}{\viipt}{\@viipt}\textregistered}$ Human v3 miRNA Expression Assay Kits, Yakov Alekseev (Syntol LLC) for sharing the nucleotide sequences of primers and probes used in the study, and Natalia Usman (Dmitry Rogachev NMRC) for valuable suggestions and recommendations.

In memoriam Alexander Globa (Syntol LLC), the developer of oligonucleotide primers and probes used in the research.

Supplementary data

Supplementary Table 1

Characteristics of patients randomly selected for the validation analysis of miR-128-3p expression by NanoString

Patient ID	Age at diagnosis, years	INSS stage	NB2004 risk group	1p deletion	MNA
263	2.48	4	High-risk group	No	No
283	0.91	3	Observation	No	No
293	3.76	4	High-risk group	No	No
311	1.11	4	High-risk group	Yes	No
346	7.86	1	Observation	No	No
376	1.81	4	High-risk group	No	No
486	2.88	4	High-risk group	No	No
577	0.17	4S	Observation	No	No
593	0.59	4S	Observation	No	No
685	0.90	1	Observation	No	No
719	4.10	4	High-risk group	No	No
755	0.24	3	Observation	No	No
783	0.35	1	Observation	No	No
789	0.94	3	Observation	No	No
790	4.46	1	High-risk group	Yes	Yes
800	0.61	3	Observation	No	No
821	0.05	1	Observation	No	No
833	5.12	4	High-risk group	No	Yes
834	3.73	1	Observation	No	No
842	0.15	4S	Observation	No	No
874	0.27	2	Observation	No	No
881	0.20	1	Observation	No	No
910	0.65	4	Intermediate risk group	No	No
986	0.77	3	Observation	No	No
994	2.72	4	High-risk group	Yes	No

References

Attiyeh

E.F.

London

W.B.

Mossé

Y.P.

et al., Chromosome 1p and 11q deletions and outcome in neuroblastoma, New England Journal of Medicine 353 (2005), 2243–2253.

Cohn

S.L.

Pearson

A.D.J.

London

W.B.

et al., The International Neuroblastoma Risk Group (INRG) classification system: An INRG task force report, Journal of Clinical Oncology 27 (2009), 289–297.

Molenaar

J.J.

Koster

Zwijnenburg

D.A.

et al., Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes, Nature 483 (2012), 589–593.

Ohira

and Nakagawara

, Global genomic and RNA profiles for novel risk stratification of neuroblastoma, Cancer Science 101 (2010), 2295–2301.

Peifer

Hertwig

Roels

et al., Telomerase activation by genomic rearrangements in high-risk neuroblastoma, Nature 526 (2015), 700–704.

Ackermann

Cartolano

Hero

et al., A mechanistic classification of clinical phenotypes in neuroblastoma, Science 362 (2018), 1165–1170.

Ohira

Oba

Nakamura

et al., Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas, Cancer Cell 7 (2005), 337–350.

Oberthuer

Juraeva

Hero

et al., Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers, Clinical Cancer Research 21 (2015), 1904–1915.

De Preter

Vermeulen

Brors

et al., Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature, Clinical Cancer Research 16 (2010), 1532–1541.

10.

Han

L.L.

Zhou

X.J.

F.J.

et al., MiR-223-3p promotes the growth and invasion of neuroblastoma cell via targeting FOXO1, European Review for Medical and Pharmacological Sciences 23 (2019), 8984–8990.

11.

Liang

Ying

et al., Downregulation of microRNA-3934-5p induces apoptosis and inhibits the proliferation of neuroblastoma cells by targeting TP53INP1, Experimental and Therapeutic Medicine 18 (2019), 3729–3736.

12.

X.L.

Zhang

X.J.

et al., MicroRNA-146b promotes neuroblastoma cell growth through targeting NUMB, Experimental and Therapeutic Medicine 19 (2020), 3531–3536.

13.

Zhou

et al., MicroRNA-429 inhibits neuroblastoma cell proliferation, migration and invasion via the NF-κB pathwa, Cellular & Molecular Biology Letters 25 (2020), 5.

14.

Kim

K.W.

Qiao

Kim

J.Y.

et al., Overexpression of microRNA-145 inhibits tumorigenesis through autophagy in chemotherapy and radiation resistant neuroblastoma cells, Oncoscience 7 (2020), 1–9.

15.

Wang

Zhang

Yao

et al., MiR-490-5p functions as tumor suppressor in childhood neuroblastoma by targeting MYEOV, Human Cell 33 (2020), 261–271.

16.

Mao

Zhang

Cheng

et al., MiR-149 inhibits cell proliferation and enhances chemosensitivity by targeting CDC42 and BCL2 in neuroblastoma, Cancer Cell International 19 (2019), 357.

17.

and Chen

, MiR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNFα, Artificial Cells, Nanomedicine and Biotechnology 47 (2019), 3072–3078.

18.

Chava

Reynolds

C.P.

Pathania

A.S.

et al., MiR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma, Molecular Oncology 14 (2020), 180–196.

19.

GeneCards. The Human Gene Database, 1996. https://www.genecards.org (accessed October 15, 2021).

20.

Hauser

Zhao

Pang

et al., Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis, PLoS One 10 (2015), e0116321.

21.

Green

Marrone

et al., Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma, Scientific Reports 5 (2015), 8534.

22.

Zhang

Liu

Niu

et al., MicroRNA-128-3p regulates mitomycin C-induced DNA damage response in lung cancer cells through repressing SPTAN1, Oncotarget 8 (2016), 58098–58107.

23.

Liu

H.T.

Xing

A.Y.

Chen

et al., MicroRNA-27b, microRNA-101 and microRNA-128 inhibit angiogenesis by down-regulating vascular endothelial growth factor C expression in gastric cancers, Oncotarget 6 (2015), 37458–37470.

24.

Dong

Cai

Tao

et al., An axis involving SNAI1, microRNA-128 and SP1 modulates glioma progression, PLoS One 9 (2014), e98651.

25.

Guidi

Muiños-Gimeno

Kagerbauer

et al., Overexpression of miR-128 specifically inhibits the truncated isoform of NTRK3 and upregulates BCL2 in SH-SY5Y neuroblastoma cells, BMC Molecular Biology 11 (2010), 95.

26.

Chen

and Wang

, miRDB – MicroRNA Target Prediction Database, 2019. https://www.mirdb.org (accessed October 15, 2021).

27.

RNAcentral: The non-coding RNA sequence database, 2010. https://www.rnacentral.org (accessed October 15, 2021).

28.

Evangelisti

Florian

M.C.

Massimi

et al., MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness, FASEB Journal 23 (2009), 4276–4287.

29.

Bao

Zhang

Meng

et al., SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p, Neurochemical Research 45 (2020), 825–836.

30.

Roy

Dunbar

Agrawal

et al., Amygdala-Based Altered miRNome and Epigenetic Contribution of miR-128-3p in Conferring Susceptibility to Depression-Like Behavior via Wnt Signaling, International Journal of Neuropsychopharmacology 23 (2020), 165–177.

31.

Keshelava

Davicioni

Wan

et al., Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide, Journal of the National Cancer Institute 99 (2007), 1107–1119.

32.

Chen

Sun

X.X.

Sears

R.C.

et al., Writing and erasing MYC ubiquitination and SUMOylation, Genes and Diseases 6 (2019), 359–371.

33.

Zhu

Z.C.

Liu

J.W.

et al., KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells, Oncogene 37 (2018), 2936–2952.

34.

Liu

Jiang

Hui

et al., Mir-758-5p Suppresses Glioblastoma Proliferation, Migration and Invasion by Targeting ZBTB20, Cellular Physiology and Biochemistry 48 (2018), 2074–2083.

35.

Zage

P.E.

Louis

C.U.

and Cohn

S.L.

, New aspects of neuroblastoma treatment: ASPHO 2011 symposium review, Pediatric Blood and Cancer 58 (2012), 1099–1105.

36.

Szemes

Greenhough

Melegh

et al., Wnt signalling drives context-dependent differentiation or proliferation in neuroblastoma, Neoplasia 20 (2018), 335–350.

37.

J.C.

Chiang

H.C.

Tseng

P.H.

et al., RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells, Carcinogenesis 35 (2014), 2807–2814.

38.

Ohira

Morohashi

Inuzuka

et al., Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: Identification of 305 genes differentially expressed between favorable and unfavorable subsets, Oncogene 22 (2003), 5525–5536.

39.

Arai

Ozaki

Niizuma

et al., ERAP140/Nbla10993 is a novel favorable prognostic indicator for neuroblastoma induced in response to retinoic acid, Oncology Reports 19 (2008), 1381–1388.

40.

Hosen

Yamane

Muijtjens

et al., Bmi-1-green fluorescent protein-knock-in mice reveal the dynamic regulation of bmi-1 expression in normal and leukemic hematopoietic cells, Stem Cells 25 (2007), 1635–1644.

41.

Park

I.K.

Morrison

S.J.

and Clarke

M.F.

, Bmi1, stem cells, and senescence regulation, Journal of Clinical Investigation 113 (2004), 175–179.

42.

Molofsky

A.V.

Bydon

et al., Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways, Genes & Development 19 (2005), 1432–1437.

43.

Dimri

G.P.

Martinez

J.L.

Jacobs

J.J.

et al., The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells, Cancer Research 62 (2002), 4736–4745.

44.

Zhang

Sui

and Xin

, Correlations of BMI-1 expression and telomerase activity in ovarian cancer tissues, Experimental Oncology 30 (2008), 70–74.

45.

Song

L.B.

Zeng

M.S.

Liao

W.T.

et al., Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells, Cancer Research 66 (2006), 6225–6232.

46.

Bhattacharya

Mustafi

S.B.

Street

et al., Bmi-1: At the crossroads of physiological and pathological biology, Genes and Diseases 2 (2015), 225–239.

47.

Itahana

Zou

Itahana

et al., Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1, Molecular and Cellular Biology 23 (2003), 389–401.

48.

Nowak

Kerl

Fehr

et al., BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas, Nucleic Acids Research 34 (2006), 1745–1754.

49.

Cui

et al., Bmi-1 is essential for the tumorigenicity of neuroblastoma cells, The American Journal of Pathology 170 (2007), 1370–1378.

50.

Bahmad

H.F.

Chamaa

Assi

et al., Cancer stem cells in neuroblastoma: Expanding the therapeutic frontier, Frontiers in Molecular Neuroscience 12 (2019), 131.

51.

Von Stedingk

Koster

Piqueras

et al., snoRNPs regulate telomerase activity in neuroblastoma and are associated with poor prognosis, Translational Oncology 6 (2013), 447–457.

52.

UniProtKB, UniProt Knowledgebase, 2002. https://www.uniprot.org (accessed October 15, 2021).

Suppressed miR-128-3p combined with TERT overexpression predicts dismal outcomes for neuroblastoma

Abstract

BACKGROUND:

OBJECTIVE:

METHODS:

RESULTS:

CONCLUSIONS:

Keywords

1. Introduction

Table 1 Nucleotide sequences of primers and probes used for reverse transcription reaction and qPCR

2.1 Experimental subjects

2.2 Molecular genetic techniques

2.3 Statistics

3. Results

Table 2 Risk indicators (EFS, CIRP) with molecular and clinical characterization of tumors for the cohort stratified by MYCN amplification (MNA) and TERT/miR-128-3p expression in non-MNA cases

5. Conclusions

Ethical statement

Author contributions

Footnotes

Acknowledgments

Supplementary data

References

Table 1
Nucleotide sequences of primers and probes used for reverse transcription reaction and qPCR

Table 2
Risk indicators (EFS, CIRP) with molecular and clinical characterization of tumors for the cohort stratified by MYCN amplification (MNA) and TERT/miR-128-3p expression in non-MNA cases